The sentinel observation of a potential pharmacogenetic interaction between NAC and TOLLIP polymorphism highlights the urgent, unmet need for better, molecularly focused, and precise therapeutic strategies in IPF. This evidence concerns the gene TOLLIP and idiopathic pulmonary fibrosis.